Lai Yongzhen, Xie Changfu, Zhang Shixian, Gan Guowu, Wu Di, Chen Weihui
Department of Oral and Maxillofacial Surgery, Union Hospital, Fujian Medical University, Fuzhou, P. R. China.
Stomatological Research Institute, Fujian Medical University, Fuzhou, Fujian Province, P. R. China.
Birth Defects Res A Clin Mol Teratol. 2016 Jul;106(7):612-23. doi: 10.1002/bdra.23504. Epub 2016 May 6.
Gain-of- and loss-of-function studies have demonstrated that changes in bone morphogenetic protein (BMP) signaling during embryo development cause craniofacial malformations, including cleft palate. It remains uncertain whether BMP signaling could be targeted pharmacologically to affect craniofacial morphogenesis.
Pregnant C57Bl/6J mice were treated with the BMP type I receptor inhibitor LDN-193189 at the dose of 3, 6, or 9 mg/kg twice a day by intraperitoneal injection from embryonic day 10.5 (E10.5) to E15.5. At E16.5, embryos were investigated by facial measurement analysis and histology to determine the optimal concentration for malformation. Subsequent embryonic phenotypes were analyzed in detail by histology, whole-mount skeletal staining, micro-computed tomography, and palatal organic culture. We further used immunohistochemistry to analyze protein expression of the BMP-mediated canonical and noncanonical signaling components.
The optimal concentration of LDN-193189 was determined to be 6 mg/kg. In utero, LDN-193189 exposures induced partial clefting of the anterior palate or complete cleft palate, which was attributed to a reduced cell proliferation rate in the secondary palate, and delayed palatal elevation caused by micrognathia. Analysis of signal transduction in palatal shelves at E12.5 and E13.5 identified a significant reduction of BMP/Smad signaling (p-Smad1/5/8) and unchanged BMP noncanonical signaling (p-p38, p-Erk1/2) after treatment with LDN-193189.
The results of this study indicate that LDN-193189 can be used to manipulate BMP signaling by selectively targeting the BMP/Smad signaling pathway to affect palatal morphogenesis and produce phenotypes mimicking those caused by genetic mutations. This work established a novel mouse model for teratogen-induced cleft palate. Birth Defects Research (Part A) 106:612-623, 2016. © 2016 Wiley Periodicals, Inc.
功能获得和功能丧失研究表明,胚胎发育过程中骨形态发生蛋白(BMP)信号的变化会导致颅面畸形,包括腭裂。BMP信号是否可以通过药物靶向作用来影响颅面形态发生仍不确定。
从胚胎第10.5天(E10.5)至E15.5,对怀孕的C57Bl/6J小鼠每天两次腹腔注射剂量为3、6或9mg/kg的BMP I型受体抑制剂LDN-193189。在E16.5时,通过面部测量分析和组织学对胚胎进行研究,以确定导致畸形的最佳浓度。随后通过组织学、整体骨骼染色、微型计算机断层扫描和腭器官培养对后续胚胎表型进行详细分析。我们还使用免疫组织化学分析BMP介导的经典和非经典信号成分的蛋白表达。
确定LDN-193189的最佳浓度为6mg/kg。在子宫内,LDN-193189暴露会导致前腭裂或完全腭裂,这归因于继发腭中细胞增殖率降低,以及小颌畸形导致的腭部抬高延迟。对E12.5和E13.5时腭突的信号转导分析发现,用LDN-193189处理后,BMP/Smad信号(p-Smad1/5/8)显著降低,而BMP非经典信号(p-p38,p-Erk1/2)未改变。
本研究结果表明,LDN-193189可通过选择性靶向BMP/Smad信号通路来操纵BMP信号,从而影响腭部形态发生并产生与基因突变所致相似的表型。这项工作建立了一种新型的致畸剂诱导腭裂小鼠模型。《出生缺陷研究(A部分)》106:612 - 623,2016年。©2016威利期刊公司。